Latest Ketamine Stories
EVANSTON, Ill., June 22, 2011 /PRNewswire/ -- Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced that it has initiated a Phase II clinical trial of its lead compound GLYX-13.
UT Southwestern Medical Center scientists are shedding new light on why the anesthetic drug ketamine produces a fast-acting antidepressant response in patients with treatment-resistant depression.
MIAMI and EVANSTON, Ill., Dec.
SAN DIEGO and EVANSTON, Ill., Nov.
Procedural sedation and analgesia is an essential element of care for children requiring painful procedures in the emergency department.
A new class of compounds identified by researchers at Emory University School of Medicine could be developed into drugs for the treatment of schizophrenia.
EVANSTON, Ill., Aug.
- A ceramic container used inside a fuel-fired kiln to protect pots from the flame.